Ziopharm Oncology Inc. (NASDAQ:ZIOP)’s share price was up 5.3% during trading on Monday . The stock traded as high as $5.21 and last traded at $5.12, with a volume of 971,009 shares trading hands. The stock had previously closed at $4.86.

Several equities analysts recently commented on ZIOP shares. Vetr downgraded shares of Ziopharm Oncology from a “strong-buy” rating to a “buy” rating and set a $9.76 price target on the stock. in a research note on Monday, April 18th. Mizuho upped their price objective on shares of Ziopharm Oncology from $6.00 to $7.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 11th. Zacks Investment Research raised shares of Ziopharm Oncology from a “sell” rating to a “hold” rating in a research report on Wednesday, May 11th. Wells Fargo & Co. reaffirmed a “sell” rating and set a $6.50 price objective on shares of Ziopharm Oncology in a research report on Thursday, May 12th. Finally, Griffin Securities reaffirmed a “buy” rating and set a $21.00 price objective on shares of Ziopharm Oncology in a research report on Thursday, May 26th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $9.55.

The company has a 50-day moving average price of $5.47 and a 200-day moving average price of $6.78. The company’s market capitalization is $636.76 million.

Ziopharm Oncology (NASDAQ:ZIOP) last released its earnings results on Tuesday, May 10th. The biotechnology company reported ($0.09) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.08) by $0.01. The firm earned $1.97 million during the quarter, compared to the consensus estimate of $1.89 million. During the same quarter last year, the firm earned ($0.69) EPS. Ziopharm Oncology’s revenue for the quarter was up 623.9% on a year-over-year basis. Equities analysts forecast that Ziopharm Oncology Inc. will post ($0.42) EPS for the current fiscal year.

Other large investors have added to or reduced their stakes in the company. Swiss National Bank boosted its stake in Ziopharm Oncology by 2.2% in the fourth quarter. Swiss National Bank now owns 159,220 shares of the biotechnology company’s stock worth $1,323,000 after buying an additional 3,500 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of Ziopharm Oncology by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 212,521 shares of the biotechnology company’s stock valued at $1,766,000 after buying an additional 3,354 shares during the period. California Public Employees Retirement System raised its stake in shares of Ziopharm Oncology by 567.2% in the fourth quarter. California Public Employees Retirement System now owns 307,366 shares of the biotechnology company’s stock valued at $2,554,000 after buying an additional 261,300 shares during the period. Finally, Morgan Stanley raised its stake in shares of Ziopharm Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock valued at $13,447,000 after buying an additional 78,583 shares during the period.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.